newsfilter
← Latest News
PR Newswire·

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN)